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Abstract
One of the main aims of the follow-up after curative resection of colorectal cancer is the early detection and treatment of
tumor recurrence. We previously demonstrated decreased preoperative soluble CD26 (sCD26) levels in serum from
colorectal cancer patients. We extended now the study to investigate if sCD26 levels in postoperative serum serve as marker
of recurrence of the disease during surveillance. Soluble sCD26 was measured in pre- and postoperative serum samples of
43 patients with primary colorectal cancer. Carcinoembryonic antigen, carbohydrate antigen 19.9 and 72.4 levels were also
measured during surveillance. The average follow-up period was 41.8620.8 months. sCD26 levels during follow-up showed
well-defined patterns in patients without disease (n = 28), and in patients with tumor persistence (n = 2), local recurrence
(n = 3) or distant metastasis (n = 10). Disease-free patients showed stable levels between 460–850 ng/mL during follow-up,
while high (over 850 ng/mL) and unstable sCD26 levels were found before recurrence was diagnosed. The mean maximum/
minimum sCD26 ratios during surveillance were 1.52, 2.12 and 2.63 for patients with no recurrence, local recurrence and
metastasis, respectively (p= 0.005). From the cut-off obtained from a receiver operator characteristics (ROC) curve built with
the maximum/minimum sCD26 ratios and the upper and lower cut-offs of sCD26, we were able to discriminate patients
with and without recurrent disease. We propose that the measurement of serum sCD26 during the follow-up of patients
diagnosed of colorectal cancer could be valuable for the early detection of local and distant recurrence. A large,
randomized, prospective trial should be performed to confirm our findings.
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Introduction
At the time of diagnosis, about 75% of colorectal cancer (CRC)
patients have the tumor confined to a portion of the bowel or to
regional lymph nodes, and can be referred for curative resection.
Unfortunately, 30–50% of those patients develop recurrence, 90%
during the first 5 years after treatment [1,2].
One of the aims of the follow-up after curative resection in CRC
patients is to improve the outcome by early detection and
treatment of recurrence. Thus postoperative surveillance must
identify asymptomatic recurrences for the early detection of locally
persistent tumors or metastases, so that further curative treatment
can be initiated and the survival rates improved. Consequently,
surveillance strategies require effective means for identifying
residual or recurrent disease. In general, meta-analyses and
reviews agree that a more intensive follow-up contributes to an
overall survival benefit [1–8].
Many different methods have been proposed for the follow-up
of CRC patients, which can be subdivided into three categories:
laboratory tests, as determination of carcinoembryonic antigen
(CEA) serum levels, other markers as the carbohydrate antigens
(CA), or liver enzymes; image tests, as ultrasound, X-ray or
computed tomography; and endoscopies. Compared to other
available diagnostic modalities, serial CEA determinations appear
to be the most sensitive for the detection of early recurrent disease
[6–8]. However, the current serum markers used to detect cancer
recurrence (CEA, TPS, CA-19.9 and CA-72.4) are not very
accurate and, in general, give rise to a considerable number of
false negatives and positives [9–10]. Therefore additional testing is
usually necessary to confirm the recurrence, generating inconve-
niences for the patients and elevating the healthcare costs, because
some of the techniques are expensive and have not been shown to
be cost-effective [11].
The protease CD26, or dipeptidyl peptidase IV (DPP-IV), EC
3.4.14.5, is a cell surface-associated glycoprotein, expressed on a
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variety of cell types including melanocytes, epithelial cells and
lymphocytes [12]. Significant levels of its soluble form (sCD26)
exist in plasma/serum and other biological fluids [13,14]. In
previous studies we detected that patients with primary CRC had
decreased sCD26 levels in preoperative serum, and showed its
value as diagnostic and prognostic marker for CRC [15] and
advanced adenomas [16]. Two independent studies confirmed
that sCD26 is among the best candidates for future blood-based
tests for early diagnosis, alone or in combination with fecal
immunochemical test (FIT) [17,18].
We had noted in our previous work that the diagnostic value of
sCD26 was worse for Dukes’ stage D patients, showing very high
levels in some individuals [15]. Here we designed a pilot study to
investigate if sCD26 level measured during the follow-up of CRC
patients (postoperative sera) is useful as marker of recurrence or
regression of the disease during cancer surveillance.
Materials and Methods
Population
Forty-three patients with primary CRC were studied, including
28 men (65.1%) and 15 women (34.9%), with a mean age of
66.4610.4 years (median = 66) (Table S1). Forty-one patients
(95.3%) were treated by curative resection (complete tumor
removal en bloc with a portion of normal bowel, mesenteric and
regional lymph nodes), and 2 (4.7%) through palliative surgery.
According to Dukes’ stage, 16.3% of the tumors were classified as
A, 46.5% as B, 25.6% as C, and 11.6% as D. Regarding the
degree of differentiation, 83.3% were moderately differentiated
and 14.3% were poorly differentiated, while 2.4% were well
differentiated. The localization of the primary tumors was: 4 in
cecum (9.3%), 1 in ascending colon (2.3%), 7 in hepatic flexure
(16.2%), 2 in splenic flexure (4.7%), 2 in descending colon (4.7%),
10 in sigma (23.3%), 5 in the rectum-sigma union (11.6%), 10 in
rectum (23.3%), and synchronic tumors in ascending colon and
cecum (2.3%), and in transverse colon and cecum (2.3%).
All patients were monitored at Complejo Hospitalario Uni-
versitario de Vigo (Spain). The study followed the clinical-ethical
practices of the Spanish Government and the Helsinki Declara-
tion, and was approved by the Galician Ethical Committee for
Clinical Research. Written Informed consent was obtained and
anonymity warranted. The clinical information collected included
Dukes’ stage, primary tumor site, type of resection, cancer
progression and chemotherapy treatment.
The standard follow-up procedure consisted on a medical
examination every 4 months during the first year, and every 6
months after that. According to the oncologist’s criteria, patients
received chemotherapy consisting on 5-fluorouracil, and in some
cases irinotecan.
Sample collection and preparation
Preoperative blood samples were collected from near but not all
the patients. Postoperative blood samples were collected at several
time points, which were not the same for each patient. Blood was
allowed to coagulate at room temperature and centrifuged at
2000 g for 15 minutes. Sera were stored at 285uC until used.
Determination of the sCD26 levels
The concentration of sCD26 was analyzed with the Human
Soluble CD26 ELISA Kit (eBioscience; Vienna, Austria) in
duplicate. Based on our previous results with this kit [15,16,19]
sCD26 values between 460–850 ng/mL were considered as
normal levels. The lower limit was established in accordance with
the 460 ng/mL cut-off suggested for our cohort of patients under
risk for CRC or with related colorectal pathologies [16], while for
the upper limit we hypothesized a 850 ng/mL cut-off for
pathological individuals (with higher levels) from our preliminary
results with CRC metastatic patients and tumor-resected patients
(reviewed in [20]).
Determination of the CEA, CA-19.9 and CA-72.4 levels
CEA and CA-72.4 were analyzed in serum using the
electrochemoluminescent immunoassay Roche Elecsys System,
and measured with a Modular Analytics E170 analyzer (Roche
Diagnostics). CA-19.9 was determined using the TRACE
BRAHMS CA 19-9 KYPTOR immunoassay (Thermo Scientific)
and measured in a Kryptor analyzer (CIS bio international).
Normal values were ,5 ng/mL for CEA, ,7 U/mL for CA-72.4,
and ,40 U/mL for CA-19.9 [7–10].
Data analysis
All the measurements included were posterior to 2 months after
surgery to allow for normalization of the marker. Statistical
analyses were performed with the SPSS package (v.19.0); tests
were two-sided; p-values,0.05 were considered significant. Chi-
square or Fischer’s exact tests were done with contingency tables.
The analysis of more than two independent samples was done with
the Kruskal-Wallis test. The maximum/minimum sCD26 con-
centration ratio was calculated for each patient to measure the
sCD26 titer stability. ROC curves and areas under the curve
(AUC) were calculated with this ratio using MedCalc (v.12.7.0).
Data from sCD26, CEA, CA-19.9 and CA-72.4 for all the
measurements during surveillance are presented on Table S2.
Results
Evolution of the cohort during the follow-up period
The average follow-up period for the 43 patients was 41.8620.8
months, with a median of 34.1 months and a range of 9.7–79.6
months (Table S1). The 2 patients treated with palliative resection
died during the study (mean 7.363.4 months). Regarding patients
treated with curative resection, after the follow-up period 28
(patients 1–28) were disease-free (68.3%; mean follow-up:
44.9619.5 months; range: 17.3–81.4 months), while local
recurrences (patients 29–31) were documented in 3 cases (7.3%;
mean follow-up: 25.763.1 months; range: 22.4–28.6 months). On
the other hand, metastases were found in 10 patients (24.4%;
mean follow-up: 44.7622.2 months; range: 15.4–79.6 months),
classified as 5 hepatic (patients 32–36), 3 pulmonary (patients 37–
39), 1 peritoneal (patient 40) and 1 in jejunum and spleen (patient
41). All these metastases were diagnosed within 3 years after
surgery, except for one liver metastasis diagnosed 4.3 years after
surgery.
Chemotherapy was given to 29 patients: 17 free of disease, 2
with local recurrence and 10 with metastases.
Tumor marker levels in preoperative blood samples
Preoperative serum samples were available for 41 patients
(Table S1), 51.2% of which showed sCD26 levels below the
460 ng/mL cut-off point (21 cases). The clinical and epidemio-
logical characteristics of these patients were analyzed according to
two groups based on the normal levels described in the previous
section: patients with positive (#460 ng/mL or .850 ng/mL) and
negative (460–850 ng/mL) preoperative sCD26. There were no
significant differences in gender, age at diagnosis, Dukes’ stage,
histological grade, tumor location, disease status or exitus between
these groups (Table 1).
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Regarding other preoperative markers, the CEA was deter-
mined in 33 patients, with 10 cases (30.3%) registering levels above
the cut-off; CA-19.9 was analyzed in 21 cases, resulting over the
cut-off in 3 cases (14.3%); and CA-72.4 appeared altered in 3 of 18
cases (16.7%). The clinical and epidemiological characteristics
were also studied according to the positivity for each of these
clinical markers (data not shown), and only the CA-72.4 and the
histological grade of the tumor showed significant differences
(p= 0.022).
Tumor marker levels in postoperative blood samples
The levels of sCD26 and the clinical CRC markers were
evaluated at the medical examinations attended by each patient
during their surveillance. The maximum/minimum sCD26
concentration ratio is included in Table S1. Analysis of these
measurements revealed trends, which allowed us to discriminate
four groups of patients:
Disease-free patients at the end of the surveillance. The
general tendency followed by disease-free patients was the
recovery of normal levels when preoperative sCD26 was low
and stable titers above 460 ng/mL but below 850 ng/mL.
Figure 1 shows the sCD26 levels during the follow-up of a
representative patient (patient 25). This tendency was observed in
22 of the 28 disease-free patients (78.6%). Moreover, the group
showed stable titers without important variations, resulting in a
mean maximum/minimum sCD26 ratio of 1.52. Figure 1 also
shows the values of CEA, CA-19.9 and CA-72.4 during the follow-
up of the representative individual. All disease-free patients
showed normal CEA levels in preoperative serum and throughout
the surveillance time. CA-19.9 and CA-72.4 were not measured in
11 of these patients, but the data available showed that levels also
tended to be stable and below the respective cut-off points, with
only one individual (patient 25) showing increased CA-72.4 levels.
Patients with tumor persistence treated with palliative
surgery. The follow-up period for the two patients did not
exceed 10 months due to their exitus. Low sCD26 levels were
characteristic in this group, remaining fairly constant. In Figure 2
(patient 42), the sCD26 levels slightly rose over the 460 ng/mL
threshold but decreased again to low values in the following
measurement. The maximum/minimum sCD26 ratio resulted in
1.17 for this patient. Although the other patient also showed
decreased sCD26 levels, only one measurement was made
posterior to 2 months after surgery; therefore, the maximum/
minimum ratio could not be calculated.
On the other hand, CEA, CA-19.9 and CA-72.4 measurements
were available for one patient (Figure 2). During follow-up this
individual showed increased CEA, while CA-19.9 and CA-72.4
displayed normal values.
Patients with recurrent tumors. The 3 patients with
recurrent tumors had a relapse time of 10.7, 25.4 and 26.6
months, respectively (patients 29–31). The evolution of the sCD26
levels is presented in Figure 3 for a representative individual
(patient 31). In this case, during follow-up and before recurrence
was diagnosed, the patients recovered normal levels (when low at
the start). However, just before recurrence was confirmed, the
three patients had a considerable increase (over 850 ng/mL in 2 of
3 cases), followed by one or two consecutive and acute decreases
(not necessarily below 460 ng/mL). Therefore, instability in
Table 1. Clinical and epidemiological characteristics of the patients according to the preoperative sCD26 levels.
Characteristic Positive preoperative sCD26 (%) Negative preoperative sCD26 (%) p value
Male 18 (69.2%) 8 (30.8%) 0.102*
Female 6 (40.0%) 9 (60.0%)
#66 years 12 (54.5%) 10 (45.5%) 0.752*
.66 years 12 (63.2%) 7 (36.8%)
Dukes A 4 (57.1%) 3 (42.9%) 0.999+
Dukes B 11 (57.9%) 8 (42.1%)
Dukes C 6 (60.0%) 4 (40.0%)
Dukes D 3 (60.0%) 2 (40.0%)
Well differentiated 0 (0.0%) 1 (100.0%) 0.381+
Moderately differentiated 21 (63.6%) 12 (36.4%)
Poorly differentiated 3 (50.0%) 3 (50.0%)
Right colon 7 (53.8%) 6 (46.2%) 0.696+
Left colon 10 (55.6%) 8 (44.4%)
Rectum 7 (70.0%) 3 (30.0%)
Disease-free 17 (65.4%) 9 (34.6%) 0.249+
Local recurrence 1 (33.3%) 2 (66.7%)
Distant metastasis 4 (40.0%) 6 (60.0%)
Tumor persistence 2 (100.0%) 0 (0.0%)
Local or distant recurrence 5 (38.5%) 8 (61.5%) 0.172*
No recurrence 17 (65.4%) 9 (34.6%)
Exitus 8 (61.5%) 5 (38.5%) 1.000*
No exitus 16 (57.1%) 12 (42.9%)
sCD26 levels were considered positive (#460 or .850 ng/mL) or negative (460–850 ng/mL).
p-values correspond to: *Fischer’s exact test; +Pearson’s Chi-square.
doi:10.1371/journal.pone.0107470.t001
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sCD26 levels preceded the appearance of recurrence. In relation
to the maximum/minimum sCD26 ratio, it increased to 2.12.
Regarding the clinical markers, CEA was found elevated in 1 of
the 3 cases, CA-19.9 also in 1 of the cases (Figure 3) and CA-72.4
in none of the patients.
Patients with metastatic disease. The group of patients
with metastasis showed another different trend. In the case of
hepatic metastases (Figure 4A; patient 34), regardless of the
preoperative sCD26 concentration, during follow-up levels
reached or widely exceeded 850 ng/mL upper normal limit (in
4 of the 5 patients; 80.0%). In the other patient, we lacked samples
from two years before the metastasis diagnosis but the last sample
showed a value near that limit and the same trend to higher values.
Therefore, the maximum/minimum sCD26 ratio for this sub-
group corresponded to 2.17, similar to that for patients with local
tumor recurrence.
In relation to the patients with pulmonary metastases (Fig-
ure 4B; patient 39) an important increase above the 850 ng/mL
upper limit was detected before the metastases were diagnosed,
followed by a decrease, suggesting unstable sCD26 levels. In this
sub-group the maximum/minimum sCD26 ratio corresponded to
2.86, higher than the previous ratios. This trend was also found in
patients with peritoneal or jejunum and spleen metastasis, with
elevated sCD26 levels during follow-up, and a maximum/
minimum sCD26 ratio of 1.48 (patient 40) and 5.34 (patient 41),
respectively.
In summary, the general tendency observed in patients with
metastasis was a sCD26 concentration over the upper 850 ng/mL
cut-off, and an overall mean maximum/minimum sCD26 ratio of
2.63 for the group. To note, all of these patients had
Figure 1. Levels of the sCD26, CEA, CA-19.9 and CA-72.4 in one
representative disease-free patient (patient 25). Black arrows
indicate beginning and end of chemotherapy cycles.
doi:10.1371/journal.pone.0107470.g001
Figure 2. Levels of the sCD26, CEA, CA-19.9 and CA-72.4 in a representative individual (patient 42) with tumor persistence. The
dashed arrow shows exitus.
doi:10.1371/journal.pone.0107470.g002
Figure 3. Levels of the sCD26, CEA, CA-19.9 and CA-72.4 in one
representative patient with local recurrence (patient 31). The
upwards arrow represents the diagnosis of recurrence, and the dashed
arrow the time of exitus.
doi:10.1371/journal.pone.0107470.g003
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chemotherapy cycles, which seemed to low sCD26 levels
transiently.
The behavior of the clinical markers in patients with metastasis
is also shown in Figures 4A and 4B for representative patients.
Despite the diagnosis of metastasis, CEA, CA-19.9 and CA-72.4
levels remained normal and stable during follow-up in 5/10, 4/10
and 7/10 patients, respectively.
ROC curve analysis for postoperative serum sCD26
Statistically significant differences were observed in the maxi-
mum/minimum sCD26 ratio between disease-free patients,
patients with local recurrence and those with metastasis
(p= 0.005). These differences were further studied using ROC
curve analysis (generated with the maximum/minimum sCD26
ratios). Only patients treated by curative surgery were included,
classified as disease-free (n = 28) or with local or distant recurrence
(n = 13). An AUC of 0.835 (95% CI 0.702–0.968; p,0.0001)
(Figure 5) was obtained, showing an optimal accuracy for
separating patients with recurrent disease. 100% sensitivity was
obtained with a maximum/minimum sCD26 ratio cut-off of 1.43
(46.4% specificity). Specificity can be further enhanced taking into
account that most false positive disease-free patients did not
overcome the 850 ng/mL cut-off. However, a higher specificity
(92.9%) was observed for the 1.98 cut-off (61.5% sensitivity).
Discussion
Numerous studies, systematic reviews and meta-analyses, as well
as the American and European cancer societies, conclude that the
best way to accomplish the early diagnosis of recurrence and
improve survival is through intensive surveillance. However,
consensus has not been achieved regarding the protocol for
intensive follow-up (combination of tests and frequency) [1–8].
In fact, the currently used clinical markers [9,10], including CA-
19.9 and CA-72.4, are neither recommended for surveillance
following curative resection nor for prognosis [5–8]. In their
guidelines, both the EGMT and ASCO groups recommend the
measurement of CEA in CRC patients in stage II or III every 2–3
months [6] or every 3 months [8] during at least 3 years after
Figure 4. Levels of the sCD26, CEA, CA-19.9 and CA-72.4 in representative patients who developed hepatic (A; patient 34) and
pulmonary (B; patient 39) metastases. Black arrows indicate beginning and end of chemotherapy cycles and the upwards arrow indicates
diagnosis of metastasis.
doi:10.1371/journal.pone.0107470.g004
Figure 5. ROC curve for the maximum/minimum sCD26 ratio
contrasting disease-free individuals and patients with local or
distant recurrence. The corresponding AUC is provided in the text.
doi:10.1371/journal.pone.0107470.g005
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diagnosis. However, there is a continuous debate around CEA
mainly due to its lack of specificity. Some authors concluded that a
rise in the antigen concentration is a poor predictor of local
recurrence, and even in patients with liver metastases a rising
concentration is a relative late phenomenon [21,22]; consequently,
serum CEA should be abandoned in routine follow-up [6]. Our
results in this study agree with this recommendation.
In our previous studies, low serum sCD26 levels were observed
in CRC patients from different cohorts: a case-control cohort [15]
and a mainly symptomatic cohort who underwent colonoscopy
[16]. In the first study, different levels of preoperative sCD26 could
be associated to increased risk of developing a recurrent disease
[15]. Additionally, we as well as others observed that some
metastatic CRC patients showed high sCD26 concentrations
[16,20]. In this pilot study we measured both the preoperative and
the postoperative sCD26 levels to assess its capability in predicting
and anticipating the diagnosis of a recurrent disease either locally
or in a distant organ. As 80% of all recurrences are diagnosed
within the first two years after surgery [8,22], we undertook a
follow-up during at least this period.
The clinical and epidemiological characteristics of the patients
(gender, age, Dukes’ stage, differentiation or localization of the
tumor) analyzed according to the preoperative sCD26 levels
rendered no association, corroborating our previous findings [15].
Although stage D patients showed higher levels compared to less
invasive tumor stages, as previously observed [15], no statistically
significant differences were found for the disease status or the
presence/absence of recurrence in relation to sCD26 positivity
based on the 460/850 ng/mL cut-off.
In relation to the sCD26 performance considering preoperative
samples, we found a reduced sensitivity for the diagnosis of CRC
in this cohort (51.2%), compared to the 81.8% observed previously
[16] or by others [17,18]. Differences may be attributed to study
settings since in this cohort only patients already diagnosed of
CRC were included, while in the other study mainly symptomatic
individuals diagnosed of diverse colorectal pathologies were
included. Alternatively, technical reasons related to the specificity
of antibodies used in the Elisa for sCD26 detection may also
explain the differences [14]. In relation to this, and as discussed
elsewhere [20], the sCD26 cut-off was changed from 410 in our
first study [15] to the 460 ng/mL [16] used here. Thus, based on
our previous results with this kit [15,16,19] sCD26 values between
460–850 ng/mL were considered normal. We preliminarily chose
the 850 ng/mL upper limit for this study because in our previous
works sCD26 levels were found within this range in non-
pathological individuals (reviewed in [20]). Also, the amount of
DPP-IV/CD26 antigen found in normal serum is consistent with
the expected values based on the specific activity of purified serum
DPP-IV [23] and there is usually correlation between DPP-IV
activity and sCD26 levels in pathological conditions [21].
Based on the proposed sCD26 normal range in the postoper-
ative measurements, we were able to define different characteristic
trends for the disease status. These were further confirmed with a
ROC curve based on the maximum/minimum sCD26 ratio that
measured sCD26 titer stability during surveillance. This analysis
showed an optimal accuracy for distinguishing disease-free patients
from those with local or distant recurrent disease. According to the
above, in most disease-free patients stable sCD26 levels (460–
850 ng/mL; maximum/minimum ratio 1.52) were found. In-
creases over 850 ng/mL were detected in 6 disease-free patients (2
cases registered increases at the end of the surveillance period and
no further information about changes in disease status could be
obtained; 2 cases were diagnosed of space-occupying lesions in the
liver with no evidence of hepatic metastasis; while no explanation
for high levels were found in the other 2 cases).
In relation to the patients with local or distant recurrence, in the
majority of the cases (10/13; 76.92%) sCD26 levels surpassed the
850 ng/mL and were unstable (maximum/minimum ratio 2.49).
Specifically, sudden increases above 850 ng/mL followed by
consecutive and acute decreases could predict recurrence at least
2–3 months before the clinical diagnosis in the 3 patients with local
recurrence. This would translate into an earlier oncological
treatment and surgical resection, with an increased survival rate
[3–5].
In the case of distant recurrences, liver and lung were the most
frequent organs affected in our cohort, consistent with 35–55% of
hepatic metastasis and 10% of lung metastasis reported for CRC
patients [24–25]. Hepatic metastases at the initial diagnosis were
detected in 3 patients and during follow-up in 2 patients. In one of
the latter, high sCD26 concentrations (reaching 3.200 ng/mL)
were observed from 2 months post-surgery and during all the
follow-up, indicating at a very early stage (more than 49 months
ahead) the suspicion of metastasis. On the contrary, in the other
patient, levels below the 460 ng/mL cut-off were found 11 months
before confirmation of metastasis, also indicating the presence of
recurrence. In two of the patients with lung metastasis, increases in
sCD26 over 850 ng/mL were registered 3.8 and 29.1 months,
respectively, before the diagnosis of metastasis; in the other case,
elevated levels (2.900 ng/mL) coincided with the diagnosis. Once
again, our test would have anticipated the diagnosis of metastasis.
Our findings suggest that the periodic measurement of serum
sCD26 levels every 3 months could serve as guide for oncological
decision-making, alerting about the appearance of recurrence
based on the maximum/minimum sCD26 ratio and the sCD26
levels during surveillance. The behavior of sCD26 according to the
disease status is summarized on Figure S1. Nonetheless, these
results should be regarded as preliminary and should be extended
to a larger dataset in further prospective and retrospective studies.
Yet, the implementation of this test to the clinical practice could be
feasible since a blood extraction is done regularly during follow-up
of CRC patients and the test consists of a typical Elisa assay.
With respect to the biological significance of our results, we have
reviewed that, pathophysiological, low sCD26 levels occur
concurrently with an impaired immune status, including some
hematological and solid malignancies, whereas increased levels
occur in inflammatory and infectious diseases, other hematological
tumors, and liver diseases such as hepatocellular carcinoma [14].
The soluble sCD26 found in serum is presumably shed by
proteolytic cleavage of the transmembrane CD26 [14,26]. Besides
the classical capillary endothelial, hepatic and immune tissues
from which sCD26 could originate [13,14,26], recently the
adipose tissue [27] and muscle [28] may also be included.
It is now clear that immune-related mechanisms are skills that
cancer cells should acquire on their way to giving rise to a tumor,
including the ability to thrive in a chronically inflamed microen-
vironment, the ability to evade immune recognition and the ability
to suppress immune reactivity. These three capabilities have been
recognized recently as the immune hallmarks of cancer [29].
Hence, for CRC we have hypothesized [14] the immune system as
the source of the impaired levels mainly because CD26 is not
differentially expressed in primary tumors and normal colon
tissues [30,31]. In addition, many in vivo studies found a
correlation between changes in serum DPP-IV activity and the
numbers of PBL, T lymphocytes, CD26+ T cells and the amount
of CD26 in T lymphocyte plasma membranes (reviewed in [14]).
Therefore, it may be possible that the developing tumor may be
immunosuppressing a sCD26-generating population or down
Serum sCD26 for Colorectal Cancer Surveillance
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regulating the production of circulating sCD26 through TGF-b
[32].
Interestingly, the elevated sCD26 concentrations found in
Dukes D CRC patients with metastasis [15] and in this work
may be related with the recent findings from Pang and colleagues
[31]. They reported differential expression of CD26 between
primary tumors and metastases. These authors identified the
CD26-expressing cells as cancer stem cells (CSC), associated with
enhanced invasiveness and chemoresistance. When isolated and
injected into mice these CD26+ cells led to the development of
distant metastasis [31]. If these cells are producing increased levels
of sCD26 it may be related to the quick expansion of the
population or perhaps because of an increased metabolism of
CD26 expression and shedding. This idea agrees and comple-
ments our findings of elevated sCD26 levels in metastatic patients.
In line with the previous report, a recently published work from
Lam and colleagues [33] reported significantly higher tumor
CD26 expression levels in CRC patients with distant metastasis
compared to non-metastatic patients. Additionally, in vitro
experiments with these CSC are ongoing in our lab to analyze
their ability to produce sCD26, which could probably explain the
elevated sCD26 concentrations found in metastatic patients.
No doubt these changes have important consequences in
oncogenic processes. Current data supports three potential roles
of sCD26 in: (i) activation–deactivation of chemokines in
inflammatory processes; (ii) activation-inactivation of other
biologically active blood substrates, growth factors or hormones;
and (iii) cell-adhesion, migration and invasion capacities [12–
14,31,34,35].
Conclusion
Serum sCD26 levels showed well-defined patterns during
follow-up of CRC patients. Stable sCD26 concentrations were
characteristic in disease-free patients; while patients with local or
distant recurrent disease showed elevated sCD26 levels with
sudden decreases, resulting in instability. The measurement of
sCD26 may help to accomplish an early detection of recurrent
CRC disease after surgery, even in patients under chemotherapy.
Once confirmed in a larger prospective trial, sCD26 could be a
valuable marker for postoperative surveillance.
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